Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2025 03:00 ET | Source: inbiome

Inbiome Shatters Diagnostic Delays: IVDR-Certified Platform IDs Bacteria in 5 Hours Across EU Hospitals

www.inbiome.com Inbiome Shatters Diagnostic Delays: IVDR-Certified Platform IDs Bacteria in 5 Hours Across EU Hospitals Hours, Not Days: EU Approval Accelerates 5-Hour Pathogen ID...
September 26, 2024 04:03 ET | Source: inbiome

Inbiome Receives FDA Breakthrough Device Designation for Revolutionary Molecular Culture ID Technology, Transforming Bacterial Diagnostics

www.inbiome.com More precise diagnostics lead to quicker, more accurate patient treatment, saving lives and improving patient outcomesUS market introduction foreseen early 2026 ...
June 20, 2024 08:00 ET | Source: AUROBAC THERAPEUTICS

AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD

The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy. Lyon (France), June 20, 2024 ...
May 21, 2024 13:49 ET | Source: Dimension Market Research

Ampicillin Market Is Expected To Reach A Revenue Of USD 480.1 Mn By 2033, At 2.4% CAGR: Insights by Dimension Market Research

New York, May 21, 2024 (GLOBE NEWSWIRE) -- Overview The Global Ampicillin Market size is expected to reach USD 388.1 million by 2024 and is further anticipated to reach USD 480.1 million by...
January 12, 2024 04:08 ET | Source: Persistence Market Research

Antibiotic Resistance Market Projected to Hit US$ 17.8 Billion by 2033 with a CAGR of 5.3% | Persistence Market Research

New York, Jan. 12, 2024 (GLOBE NEWSWIRE) -- The growing demand for new antibiotic therapies to combat antibiotic resistance is a prominent driver in the global market. In a July 2023 Science Daily...
October 18, 2023 08:00 ET | Source: Mushrooms Inc.

Mushrooms Inc (OTC:MSRM) Announces Full Patent Filing for Groundbreaking Mycelium Technology Providing Bacterial Detection and Nutrient Delivery

ESTERO, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- via IBN -- Mushrooms Inc., (OTC: MSRM) a leader in mycelium research and development, proudly announces the successful filing of its non-provisional...
March 31, 2020 16:45 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
March 16, 2020 08:45 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update

CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
February 26, 2020 16:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Present at March Investor Conferences

CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
January 13, 2020 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense

CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...

Next Page keyboard_arrow_right